LDLR and metabolic syndrome: SeF3 was able to effectively counteract dyslipidemia, one of the main MetS features, due to sterol content (Stigmastan-3,5-dien; Stigmasta-5,22-dien-3-ol, acetate, (3β)-; Ergost-5-en-3-ol, acetate, (3β, 24R)-), because these compounds reduce the incorporation of dietary and biliary cholesterol into circulating micelles, which leads to a decrease in the synthesis and absorption of cholesterol, increases LDL receptor activity, which in turn reduces the serum concentration of LDL-cholesterol [36].